A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma

Trial Profile

A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=36) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 08 Dec 2015 Results of phase I portion of this trial were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 17 Sep 2015 No of arms changed from 2 to 3 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top